Previous 10 | Next 10 |
The FDA has granted orphan drug designation to Amryt's (AMYT) AP103 for the treatment of Dystrophic Epidermolysis Bullosa ((DEB)), a subset of EB.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved. AP103 is based o...
Amryt Granted Orphan Drug Designation by the FDA for AP103 DUBLIN, Ireland, and Boston MA, December 23, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients su...
Amryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia DUBLIN, Ireland, and Boston MA, December 17, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commerci...
TR-1: S tandard form for notification of major holdings Please send the completed form together with this annex to the FCA at the following email address: Majorshareholdings@fca.org.uk . Please send in Microsoft Word format if possible. ...
Amryt (AMYT) has received marketing authorisation approval from the Brazilian Health Regulatory Agency for Lojuxta (lomitapide). Lojuxta has been approved as an adjunct to a low-fat diet and other lipid-lowering treatments, with or without low density lipoprotein apheresis, to reduce low-dens...
Amryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil DUBLIN, Ireland, and Boston MA, December 09, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeuti...
Amryt (AMYT) inks securities purchase agreements with institutional investors for the private placement of 3.2M ADSs, each representing five ordinary shares, at a purchase price of $12.50/ADS, yielding expected gross proceeds of $40M.Proceeds will be used for working capital and general corpo...
Amryt Announces $40m Private Placement with Leading Biotech Investors DUBLIN, Ireland, and Boston MA, December 8, 2020, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat pat...
Amryt Pharma (AMYT): Q3 GAAP EPS of -$0.07.Revenue of $49.33M (+470.9% Y/Y)Press Release For further details see: Amryt Pharma reports Q3 results
AMRYT REPORTS RECORD Q3 2020 RESULTS 19% YoY revenue growth in the quarter to $49.3M Raising full year revenue guidance to $180M - $182M Both metreleptin and lomitapide driving revenue performance and growth Strong cash generation with cash of $75.4M at Sep...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...